GSK shares dive as pre-tax profit falls 19%
The British pharmaceutical company reported a decline in profits and vaccine sales despite beating analyst expectations for core operating profit and earnings per share.

GSK shares fell as much as 7% on Wednesday, ending the day with a 3.8% drop, making it the second-biggest faller on the FTSE 100 index. The company reported a 19% decline in pre-tax profit to £1.9bn for the July to September quarter. This period also included £318m of restructuring charges, with more expected to follow.
Turnover for the third quarter rose 5% to £8.9bn, driven by sales of HIV, cancer, and lupus medications. However, vaccine sales dipped 2% to £2.6bn. Sales of the shingles shot Shingrix fell 5%, and the RSV vaccine Arexvy dropped 24%, partly due to tough year-on-year comparisons.
CEO Luke Miels said the impact of restructuring in the UK was relatively limited, involving some cuts to human resources and procurement jobs at the London headquarters and hubs in Poland and India. The company is also reorganising its vaccine business in Belgium, where the use of digital tools and automation is expected to lead to about 1,200 job losses.
Miels said the company is slightly ahead on a three-year cost reduction plan to save £1.9bn a year. The restructuring will cost the company £2.4bn, with most charges occurring this year and next. GSK has a goal to generate more than £40bn in total annual revenue by 2031 as it rebuilds its cancer business.
Investors expressed concern regarding the loss of patent protection for the HIV drug dolutegravir towards the end of the decade. This loss would allow other drugmakers to produce cheaper, generic versions. Miels noted that Shingrix has the potential to grow next year and mentioned two large studies to assess its effects on dementia risk and cardiovascular events.
Key facts
- GSK reported a 19% decline in pre-tax profit to £1.9bn for the July to September quarter.
- Third quarter turnover rose 5% to £8.9bn.
- Vaccine sales fell 2% to £2.6bn.
Three perspectives
Neutral
GSK reported a 19% decline in pre-tax profit to £1.9bn for the July to September quarter despite a 5% rise in turnover.
Positive
Core operating profit and core earnings per share rose 5% and 1% respectively, beating analysts' expectations.
Negative
Shares dived as much as 7% on Wednesday following reports of declining vaccine sales and restructuring charges.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.